Schlagwort: Impact Life Sciences

Ningaloo Biosystems’ technology enables the control of biological processes in living cells using light, thereby improving the productivity, quality, scalability, and reliability of pharmaceutical...

The patent cliff signifies the expiry of patent protection for major drugs, causing revenue drops as generics enter the market. Pharma companies face challenges...

A major challenge for companies in life sciences is to live through the long years of turning innovation into clinical studies and subsequently into...

The biotech sector is powering a strong first half year for the Swiss venture capital market. With CHF 705 million in invested capital, the...

European countries, especially Germany, invest billions annually in basic and translational research. The scientific quality is high, the researchers are world-class, and the infrastructure...

Biotechnology is one of the most promising key industries – with the potential to achieve medical breakthroughs, establish new production processes and shape a...

Tubulis wants to improve the efficacy of cancer therapies by using antibody drug conjugates (ADCs). Three pipeline products are currently in clinical development. ‘We...

The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory momentum, and investor confidence, this once-niche field is now positioned to...

Ghazaleh Madani, CEO of the biotech start-up CanChip, which was founded in 2023, says she is on a mission to revolutionise cancer research with...

mbiomics, based in Neuried near Munich, is pursuing an innovative ‘microbiome engineering’ approach. The company leverages state-of-the-art analytical techniques to precisely develop bacterial consortia...

The animal health market is booming – and it’s quickly emerging as an attractive investment opportunity for venture capital firms. Two portfolio companies backed by MIG...

Telling a catchy equity story and starting to address different investor groups at an early company development stage – how European life sciences companies...

Our first special issue 'Life Sciences' features a cover interview with Ghazaleh Madani, founder of CanChip. She was awarded the German Startup Award as...

Die 2022 gegründete ASTRA Therapeutics AG hat sich erfolgreich eine Seed-Finanzierung in Höhe von 7,75 Mio. CHF gesichert! MIG Capital investiert dabei gemeinsam mit Digitalis...

Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase 1 clinical trial...